ConductScience.org, home

Paper27192518

Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review.

Sisti A and 2 others. An Bras Dermatol, 2016. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. Papers, record 27192518. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27192518

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review.
PubMed
Journal
An Bras Dermatol
PubMed
Year
2016
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
1.52
iCite
Revised in PubMed
2019-11-20
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sisti AAndrea
2Sisti GGiovanni
3Oranges CMCarlo Maria

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunosuppressive AgentsMajor topic
Skin PigmentationMajor topic
TacrolimusMajor topic
VitiligoMajor topic
Administration, Cutaneous
Female
Humans
Male
Ointments
Reproducibility of Results
Treatment Outcome

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121352308Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo.J Dermatol2011https://conductscience.org/library/papers/21352308PubMed
218727812Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects.Dermatol Ther2008https://conductscience.org/library/papers/18727812PubMed
312399684Repigmentation of vitiligo with topical tacrolimus.Dermatology2002https://conductscience.org/library/papers/12399684PubMed
412756094A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.Arch Dermatol2003https://conductscience.org/library/papers/12756094PubMed
518779885Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study.Acta Derm Venereol2008https://conductscience.org/library/papers/18779885PubMed
625003059Concise review of recent studies in vitiligo.Qatar Med J2013https://conductscience.org/library/papers/25003059PubMed
721533297Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color.J Drugs Dermatol2011https://conductscience.org/library/papers/21533297PubMed
816476357[Vitiligo. Treatment of 12 cases with topical tacrolimus].Actas Dermosifiliogr2005https://conductscience.org/library/papers/16476357PubMed
917875902Focal acne during topical tacrolimus therapy for vitiligo.Arch Dermatol2007https://conductscience.org/library/papers/17875902PubMed
1024150824[Off-label indications for topical tacrolimus].Hautarzt2013https://conductscience.org/library/papers/24150824PubMed
1116120133
FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo.
Br J Dermatol2005https://conductscience.org/library/papers/16120133PubMed
1218327009Tacrolimus-induced hyperpigmentation in a patch of vitiligo.Skinmed2008https://conductscience.org/library/papers/18327009PubMed
1315660910Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo.Pediatr Dermatol2005https://conductscience.org/library/papers/15660910PubMed
1421965863Effect of 0.1% tacrolimus ointment in localized vitiligo: an open uncontrolled trial.Indian J Dermatol2011https://conductscience.org/library/papers/21965863PubMed
1518789070Topical immunomodulators are effective for treatment of vitiligo.J Dermatol2008https://conductscience.org/library/papers/18789070PubMed
1619496898Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.J Eur Acad Dermatol Venereol2009https://conductscience.org/library/papers/19496898PubMed
1724860752Hyperpigmentation in photo exposed patches of vitiligo following tacrolimus therapy.Indian Dermatol Online J2014https://conductscience.org/library/papers/24860752PubMed
1821457214A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo.Br J Dermatol2011https://conductscience.org/library/papers/21457214PubMed
1920175845Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo.J Dermatol2010https://conductscience.org/library/papers/20175845PubMed
2015243524Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.J Am Acad Dermatol2004https://conductscience.org/library/papers/15243524PubMed

See all 34 referencesDownload CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
42219812Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025).J Dermatol2026https://conductscience.org/library/papers/42219812PubMed
41996020Early Proteomic Alterations in Non-segmental Vitiligo Skin Following Treatment with Topical Tacrolimus.Dermatol Ther (Heidelb)2026https://conductscience.org/library/papers/41996020PubMed
40740404Recent Advances in Management of Vitiligo.Indian J Dermatol2025https://conductscience.org/library/papers/40740404PubMed
40172744Impacts of Topical Treatments and Phototherapy on Stratum Corneum Hydration, Sebum and Elasticity in Vitiligo Skin.Dermatol Ther (Heidelb)2025https://conductscience.org/library/papers/40172744PubMed
38839628The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review.Inflamm Res2024https://conductscience.org/library/papers/38839628PubMed
38178870Antioxidant mechanisms of mesenchymal stem cells and their therapeutic potential in vitiligo.Front Cell Dev Biol2023https://conductscience.org/library/papers/38178870PubMed
36865864Melanogenesis and Hypopigmentation: The Case of Vitiligo.Indian J Dermatol2022https://conductscience.org/library/papers/36865864PubMed
33911786The Role of MicroRNAs in Vitiligo: Regulators and Therapeutic Targets.Ann Dermatol2020https://conductscience.org/library/papers/33911786PubMed
32705792Macrophage inhibitory factor (MIF) gene polymorphisms are associated with disease susceptibility and with circulating MIF levels in active non-segmental vitiligo in patients from western Mexico.Mol Genet Genomic Med2020https://conductscience.org/library/papers/32705792PubMed
30238584A preliminary study of fractional CO2 laser added to topical tacrolimus combined with 308 nm excimer lamp for refractory vitiligo.Dermatol Ther2019https://conductscience.org/library/papers/30238584PubMed
29464168Treatment Strategies for Hypopigmentation in the Context of Burn Hypertrophic Scars.Plast Reconstr Surg Glob Open2018https://conductscience.org/library/papers/29464168PubMed
28217552Effectiveness and safety of topical tacrolimus in treatment of vitiligo.J Adv Pharm Technol Res2017https://conductscience.org/library/papers/28217552PubMed
28029168Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization.Med Res Rev2017https://conductscience.org/library/papers/28029168PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/27192518

GET https://conductscience.org/api/papers/v1/27192518/references?page=2